Over the past quarter, six of the eight major Wall Street brokerages that cover Johnson & Johnson have upgraded their ratings, raising the proportion of “Buy” recommendations to 75%. This follows Jim Cramer’s recent call to pivot into legacy healthcare firms deploying AI, where he specifically highlighted J&J’s advancements in oncology. Increased sell-side enthusiasm has been reflected in an average target price revision of +12% since November, suggesting analysts expect sustained revenue growth driven by J&J’s pharmaceutical and medical device segments.

In 2023, Johnson & Johnson completed its largest corporate restructuring in 35 years with the spin-off of its consumer health business into Kenvue. This move sharpened J&J’s focus on higher-margin pharmaceuticals and medical devices, which together accounted for 88% of total adjusted operating profit in fiscal 2024. Management has guided for mid-single-digit revenue growth in 2026, supported by a projected 8% compound annual growth rate in immunology products and a 6% CAGR in surgical devices.

Johnson & Johnson has committed $1.7 billion over three years to expand its digital therapeutics and AI research, with an emphasis on cancer diagnostics and personalized treatment algorithms. During the fourth quarter, the company reported initiation of five new clinical studies leveraging machine-learning models to predict patient response in solid tumors. Jim Cramer noted J&J’s use of artificial intelligence in its oncology pipeline as a key differentiator, forecasting that these data-driven approaches could accelerate time-to-market by up to 18 months compared with traditional development timelines.